AstraZeneca and Ionis Think They Have A Best-In-Class PCSK9 Challenger To Novartis’s Leqvio

Study Shows 73% Reduction in LDL Cholesterol

 
• By Andrew McConaghie
  
Ionis HQ
The candidate is the latest to come out of Ionis' antisense oligonucleotide pipeline, and could be a strong challenger to Novartis's Leqvio. • Source: Ionis
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip